Your latest cannabis business info from Europe

Your latest cannabis business info from Europe


Unknown and dangerous? H4-CBD and THCP in France

Unknown and dangerous? H4-CBD and THCP in France

The fact that new substances, such as and H4-CBD and THCP have already entered the market in France, after Hexahydrocannabinol (HHC) was banned just one month ago is troubling. These products do not, however, come without dangers as doctors have advised. The customers accidentally end up acting as testers for other possibilities.

The HHC ban and quick market response in France

The selling of HHC, a chemical from cannabis that had similar effects to the plant itself, is not legal in France since June 13th. It immediately became popular as an actual substitute for cannabis users. However, soon after worries about this synthetic substance’s safety surfaced, we could observe the prohibition. After that, shoppers in specialised stores went into a frenzy and quickly ran through the remaining supplies.

Despite the ban, HHC’s absence wasn’t influential for very long. Suppliers quickly offered a substitute: H4-CBD, a synthetic substance made from CBD and chemically modified. It’s crucial to keep in mind that these substitutes don’t include any natural ingredients, as sellers acknowledge. Shop owners are aware of the short shelf lives of these products and the ongoing game of cat and mouse between producers and authorities. The market is driven by consumer desire for alternatives, leaving businesses to negotiate confusing regulatory areas.

The risks and concerns about H4-CBD and THCP

Medical experts in France caution about the potential risks posed by H4-CBD and THCP. As cannabinoids, H4-CBD and THCP have an effect on our neurological system and perception. Doctors warn that these substances may cause serious risks. They are essentially poor imitations of the molecular structure of THC, CBD, or both. These dangers include not only possible addiction. We may also speak about cardiovascular, neuropsychiatric, and other issues. There hasn’t been enough research done on these substances. Thus, people accidentally act as test subjects without being aware of the potential consequences.

These chemicals are already subject to increased supervision, according to the French National Agency for the Safety of Medicines and Health Products (ANSM). Expert analyses are currently being conducted, and results should be available by year’s end. This regulatory review emphasises the critical need for comprehensive scientific studies to inform policy choices about these new substances.

Thus, consumers are in danger because of the quick introduction of such substances, which lack adequate research and regulatory control. Authorities, health care providers, and patients must all have extreme caution.


German cannabis legislation: opposition’s concerns


Germany: protection zones with the “Bubatzkarte”

Promising future of medical cannabis in Spain: €335 Million by 2030